BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer

Non–Small Cell Lung Cancer, Version 2.2013

(2017) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN  That Induce PD-L1 Expression in Head and Neck Cancer

(2015) F. Concha-Benavente et al.   CANCER RESEARCH

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients

(2015) Yunlong Jia et al.   INTERNATIONAL JOURNAL OF CANCER

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

PD-L1 expression as a potential predictive biomarker

(2015) Alberto Fusi et al.   LANCET ONCOLOGY

Is PD-L1 Expression a Biomarker of Response?

(2015)   Cancer Discovery

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

(2014) M. V. Dieci et al.   ANNALS OF ONCOLOGY

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Amphiphysin 2 (BIN1) in physiology and diseases

(2014) Ivana Prokic et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Ethanol extract of Forsythia suspensa root induces apoptosis of esophageal carcinoma cells via the mitochondrial apoptotic pathway

(2014) LIANMEI ZHAO et al.   Molecular Medicine Reports

Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease

(2013) Meng-Shan Tan et al.   TRENDS IN MOLECULAR MEDICINE

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Methylation signature of lymph node metastases in breast cancer patients

(2012) Zeinab Barekati et al.   BMC CANCER

Unknown

(2012) Ke Pan et al.   MOLECULAR MEDICINE

Increased Levels of Tumor-Infiltrating Lymphocytes are Associated with Improved Recurrence-Free Survival in Stage 1A Non-Small-Cell Lung Cancer

(2011) Zachary D. Horne et al.   JOURNAL OF SURGICAL RESEARCH

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

(2010) Yan Zhang et al.   Cellular & Molecular Immunology

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage

(2009) E K Cassimere et al.   CELL DEATH AND DIFFERENTIATION

Antitumor effects and immunoregulation mechanisms of IL-23 gene in mouse mammary cancer mediated by retrovirus

(2009) Lihua Liu et al.   CELLULAR IMMUNOLOGY

Yin-Yang of costimulation: crucial controls of immune tolerance and function

(2009) Roza I. Nurieva et al.   IMMUNOLOGICAL REVIEWS

CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study

(2009) Luigi Laghi et al.   LANCET ONCOLOGY